prgn-2009
Generic: Gorilla-derived Adenovirus-expressing HPV-16/18 E6/E7 Vaccine·Code: PRGN-2009
prgn-2009: developed by 1 company · 1 clinical trial tracked.
prgn-2009 evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect prgn-2009 to PGEN; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could prgn-2009 → PGEN affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence4 indications · 1 study sponsors
Related indications
Study sponsors
Development Pipeline (1)
| Company | Phase |
|---|---|
| PRECIGEN, INC. (PGEN) | Phase 2 |
Clinical Trials (1)
Phase I/II Trial of HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PD-L1/TGF-Beta Trap (M7824) in Subjects With HPV Positive Cancers
Primary endpoint: Safety and recommended phase II dose of PRGN-2009
Interventionalopen39 targetStarted 2020-08Completion 2026-031 site · United StatesNational Cancer Institute (NCI)
Frequently asked questions
Who is developing prgn-2009?
prgn-2009 is being developed by PRECIGEN, INC..
How many clinical trials involve prgn-2009?
BioSniper tracks 1 clinical trial involving prgn-2009.